New Stock News | Rongtai Pharmaceuticals Plans to List in Hong Kong. China Securities Regulatory Commission requires additional explanation on the reasonableness of the price at which new shareholders have entered in the past year.

According to the Smart Finance and Economics APP, on November 14, the China Securities Regulatory Commission announced the "Requirements for Supplementary Materials for Overseas Issuance and Listing Record Filing (November 10, 2025 - November 14, 2025)". The International Department of the China Securities Regulatory Commission published the requirements for supplementary materials for 10 companies, including mentioning the requirement for Rongtai Pharmaceutical to supplement the rationality of the offering price for new shareholders in the past 12 months. According to the Hong Kong Stock Exchange disclosure on September 26, Guangdong Rongtai Pharmaceutical Co., Ltd. submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citi Securities as its exclusive sponsor.